Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Front Endocrinol (Lausanne) ; 12: 800376, 2021.
Article in English | MEDLINE | ID: covidwho-1662577


Background: Although genetic diseases are rare, children with such conditions who get infected with COVID-19 tend to have a severe illness requiring hospitalization. Osteogenesis imperfecta (OI) is a rare genetic disorder of collagen resulting in fractures and skeletal deformities. Kyphoscoliosis, restrictive lung disease, and pneumonia worsen the prognosis of patients with OI. The use of bisphosphonate improves bone mineral density (BMD) and reduces fractures in OI. There is no literature describing the impact of COVID-19 in patients with OI. Methodology: A retrospective multi-center study was performed in three hospitals in Jeddah and Riyadh, Saudi Arabia, from March 1st, 2020, until August 31st, 2021, aiming to evaluate the outcome of COVID-19 in patients with OI. Demographics, vaccination status, underlying kyphoscoliosis, functional status, use of bisphosphonate, BMD, and COVID-19 severity, and course were recorded for all patients. Results: Twelve cases of confirmed COVID-19 were identified among 146 patients with OI. 9 (75%) of patients were less than 18 years, 6 (50%) were male, 5 (41%) had kyphoscoliosis, and 5 (41%) were wheelchair-bound. 6 (50%) received bisphosphonate, and 7(58%) had normal BMD. All patients had mild disease and did not require hospitalization. None of OI the patients with COVID-19 were fully vaccinated before the infection, and some were ineligible for vaccination. Conclusion: Patients with OI and COVID-19 in our study recovered without complications, unlike patients with other genetic diseases. Young age and mild illness contributed to the favorable outcome. Half of the patients received bisphosphonate and had normal BMD.

COVID-19/complications , Osteogenesis Imperfecta/therapy , SARS-CoV-2/isolation & purification , Adolescent , Adult , Bone Density , COVID-19/transmission , COVID-19/virology , Child , Diphosphonates/therapeutic use , Female , Follow-Up Studies , Fractures, Bone/drug therapy , Fractures, Bone/etiology , Fractures, Bone/pathology , Hospitalization , Humans , Male , Osteogenesis Imperfecta/epidemiology , Osteogenesis Imperfecta/virology , Prognosis , Retrospective Studies , Saudi Arabia/epidemiology , Young Adult
Balkan Med J ; 37(6): 348-350, 2020 10 23.
Article in English | MEDLINE | ID: covidwho-895573


Background: Coccydynia is a painful condition of the sacrococcygeal region, with symptoms associated with sitting and rising from a seated position. It is frequently related to trauma and idiopathic causes, and the pain is mostly chronic. Percutaneous vertebroplasty and sacroplasty are the methods that are widely used for treating compression fractures and sacral insufficiency fractures, respectively. However, the success of polymethylmethacrylate injection in the treatment of osteoporotic coccyx fractures and coccydynia is still unknown. Case Report: A 68-year-old man was admitted to our clinic with complaints of pain in the sacrococcygeal and perianal regions. In the imaging studies, a fracture line in the fifth sacral and first coccygeal segments was observed as evidenced by a bony edema. Since the patient's pain did not improve with conservative methods, we treated him with coccygeoplasty. No complication was encountered. The day after the operation, he was discharged from the hospital with complete pain relief. The patient confirmed having no pain on the third postoperative month and so did not need any analgesics. Conclusion: Coccyceoplasty may be a good treatment option for retractable pain in patients with acute or subacute osteoporotic coccygeal fractures and coccydinia with edema.

Bone Cements/standards , Coccyx/drug effects , Fractures, Bone/drug therapy , Polymethyl Methacrylate/pharmacology , Aged , Coccyx/physiopathology , Fractures, Bone/physiopathology , Humans , Male , Pain Management/instrumentation , Pain Management/methods , Pain Management/standards , Pain Measurement/methods , Polymethyl Methacrylate/therapeutic use